Genmab A/S
Genmab A/S (GMAB): 35 pipeline candidates · 15 upcoming catalysts · 42 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 1.20 · 0% dilution
Lead: Phase 3
35 candidates
15 upcoming, next in ~622d
N/A
A transparent, data-derived signal for Genmab A/Sacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$15.4B
Cash
$1.7B
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (35 candidates)
| Drug | Phase |
|---|---|
| 5-fu | Phase 1/Phase 2 |
| acasunlimab | Phase 3 |
| acasunlimab | Phase 1 |
| bendamustine | Phase 3 |
| cc-99282 | Phase 2 |
| daratumumab | Phase 1/Phase 2 |
| epcoritamab | Phase 1 |
| epcoritamab | Phase 1 |
| gen1042 | Phase 1 |
| gen1042 | Phase 1/Phase 2 |
Showing 10 of 35 candidates. Sign up for full pipeline.
Upcoming Catalysts (15)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
270
Total value held
$1.60B
| Holder | Shares | Value |
|---|---|---|
| alliancebernstein l.p. | 9,557,149 | $294.4M |
| arrowstreet capital, limited partnership | 4,975,324 | $133.5M |
| blackrock, inc. | 4,536,565 | $121.7M |
| renaissance technologies llc | 4,414,550 | $118.4M |
| deep track capital, lp | 3,663,250 | $98.3M |
| deerfield management company, l.p. | 2,462,000 | $66.1M |
| first trust advisors lp | 2,461,342 | $66.0M |
| two sigma investments, lp | 2,339,432 | $62.8M |
| morgan stanley | 2,184,701 | $58.6M |
| federated hermes, inc. | 1,251,590 | $33.6M |
Showing top 10 of 270 institutional holders of Genmab A/S. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Genmab A/S's pipeline?
Genmab A/S (GMAB) has 35 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Genmab A/S's lead drug candidate?
Genmab A/S's most advanced tracked candidate is 5-fu (Phase 1/Phase 2) for Malignant Solid Tumor.
What is Genmab A/S's next catalyst?
Genmab A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri" — expected March 1, 2028.
What is Genmab A/S's market capitalization?
Genmab A/S's market capitalization is approximately $15.4B.
Who is the CEO of Genmab A/S?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Genmab A/S (GMAB).
Get the full picture on Genmab A/S
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.